---
title: "OGEN.US (OGEN.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/OGEN.US/news.md"
symbol: "OGEN.US"
name: "OGEN.US"
parent: "https://longbridge.com/en/quote/OGEN.US.md"
datetime: "2026-05-20T12:05:37.174Z"
locales:
  - [en](https://longbridge.com/en/quote/OGEN.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/OGEN.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/OGEN.US/news.md)
---

# OGEN.US (OGEN.US) — Related News

### [Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device](https://longbridge.com/en/news/286915159.md)
*2026-05-19T12:43:01.000Z*
> Oragenics has initiated Phase IIa dosing of ONP-002 in Australia, with a cash balance of $6.1M and a Letter of Intent fo

### [Oragenics | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/285768695.md)
*2026-05-08T20:04:11.000Z*
### [Oragenics Doses First Patient In Phase 2a Trial For Brain Injury Drug ONP-002](https://longbridge.com/en/news/282660503.md)
*2026-04-14T09:10:16.000Z*
> Oragenics Inc. has initiated the Phase 2a trial for ONP-002, its lead candidate for treating concussions and mild trauma

### [Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | OGEN Stock News](https://longbridge.com/en/news/280534961.md)
*2026-03-25T14:30:35.000Z*
> Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | OGEN Stock News